Johnson & Johnson (JNJ), Wednesday announced that it has completed its acquisition of Intra-Cellular Therapies, Inc., which will now operate as a business unit within Johnson & Johnson Innovative Medicine.
Following the acquisition, Intra-Cellular's CAPLYTA, an FDA-approved drug for depressive episodes associated with bipolar I or II disorder, will be a part of JNJ's robust portfolio of differentiated medicines.
The company expects the transaction to accelerate its 2025 sales growth by approximately 0.8 percent with approximately $0.7 billion in incremental sales.
Moreover, the company expects the transaction to be accretive to dilute adjusted earnings per share by approximately $0.25 in 2025, and approximately $0.21 earnings per share in 2026.
With the completion of the acquisition, Intra-Cellular Therapies' common stock ceased trading on the NASDAQ Global Select Market.
In the pre-market hours, JNJ's stock is trading at $153.26, up 0.01 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.